Stockscreener 앱 받기
132.82
1.48%
1.94
시장 영업 전:
132.43
-0.39
-0.29%
전일 마감가:
$130.88
열려 있는:
$131.91
하루 거래량:
9.80M
Relative Volume:
1.45
시가총액:
$223.47B
수익:
$42.34B
순이익/손실:
$13.50B
주가수익비율:
17.23
EPS:
7.71
순현금흐름:
$6.66B
1주 성능:
+3.08%
1개월 성능:
+0.67%
6개월 성능:
+11.99%
1년 성능:
+25.40%
1일 변동 폭
$131.33
$136.80
1주일 범위
$128.00
$136.80
52주 변동 폭
$99.71
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
132.82 | 223.47B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.93 | 150.72B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
378.22 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
84.85 | 107.15B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.65 | 44.54B | 5.54B | 4.18B | 259.90M | 7.00 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Positive Legal and Market Factors Justify Buy Rating for Abbott Laboratories - TipRanks
Judge Allows Testimony That Abbott, Mead Johnson Baby Formula Caused Disease - Insurance Journal
Abbott (ABT) Launches Rapid Concussion Test with MotoAmerica - GuruFocus
Abbott Nutrition Reaches Deal With FDA To Reopen Baby Formula Plant Amid Shortage - Class Action Lawsuits
2 Stocks, 2 Decades, $200. Is This the Long-Term Dividend Play for Your Portfolio? - The Motley Fool
Abbott Laboratories Director Makes Significant Stock Sale! - TipRanks
Abbott Beats Bellwether In Formula MDL Ahead Of Trial - Law360
US judge allows testimony that Abbott and Mead Johnson preterm baby formula caused deadly disease - Reuters
Abbott Laboratories (ABT) Sees Stock Rise Following Favorable Court Ruling - GuruFocus
Abbott gains after upcoming baby formula case thrown out (ABT:NYSE) - Seeking Alpha
Abbott Laboratories First Quarter 2025 Earnings: EPS Misses Expectations - simplywall.st
Stroke Management Market Is Booming Worldwide | Abbott - openPR.com
Investors in Abbott Laboratories (NYSE:ABT) have seen notable returns of 52% over the past five years - Yahoo Finance
Abbott Laboratories Announces Executive Vice President’s Retirement - TipRanks
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races - Yahoo Finance
Abbott Laboratories (ABT): Among the Best Stocks to Buy During Recession - Yahoo Finance
Abbott Laboratories price tries to shake off negative pressureForecast today01-05-2025 - Economies.com
MotoAmerica: More On Abbott Blood Test for Rapid Concussion Evaluation On-Site - Roadracing World
Abbott Laboratories (ABT): Jim Cramer Calls It a ‘Tour de Force’ — Why He’s Still Amazed at This Stock - Yahoo Finance
Abbott Laboratories (ABT) Announces Results of Annual Shareholders Meeting - GuruFocus
Abbott (ABT) Integrates Libre CGM Data with Epic's Health Records - GuruFocus
Abbott signs deal with Epic for CGM data integration (ABT:NYSE) - Seeking Alpha
Abbott Integrates Libre CGM’s Data with Epic’s EHR System - Medical Product Outsourcing
Abbott (ABT) Teams Up with Epic for Advanced Health Data Integra - GuruFocus
Abbott integrates Libre CGM data into Epic EHR workflows - Drug Delivery Business
Abbott Partners With Epic to Transform Diabetes Care for 280M Patients | ABT Stock News - Stock Titan
Sevoflurane Market Overall Study Report 2025-2032 | Abbott Laboratories, Baxter, Piramal Pharma Solutions - openPR.com
A Look Into Abbott Laboratories Inc's Price Over Earnings - Benzinga
Abbott Laboratories (NYSE:ABT) Unveils Breakthrough Leadless Pacemaker Advances In New Clinical Trials - simplywall.st
3 Dividend Stocks to Buy and Hold for the Next Decade - Yahoo Finance
Abbott (ABT) Unveils Promising Results from Leadless Pacemaker S - GuruFocus
The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic - Yahoo Finance
Drug Eluting Stents Market Overall Study Report 2025-2032 | - openPR.com
Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price - Yahoo Finance
Abbott Laboratories Insiders Sold US$3.3m Of Shares Suggesting Hesitancy - simplywall.st
The health care sector is a mixed picture, but Abbott Labs is a buy. - Forbes
Abbott Stuns with Study Results in PFA Market: Is It Enough? - Medical Device and Diagnostic industry
Pesticides Market to Experience Rapid Growth Driven by Abbott - openPR.com
Abbott Laboratories Says Investigational Pacemaker Shows Safety, Performance - marketscreener.com
India Medical Nutrition Market Overall Study Report 2025-2032 | - openPR.com
Abbott has positive study results for Aveir CSP leadless pacemaker - MassDevice
Abbott Laboratories: Strategic Advancements and Market Positioning with Volt PFA Platform Drive Buy Rating - TipRanks
Abbott announces new data from its Volt CE Mark Study - TipRanks
Breakthrough Heart Technology: Abbott's Leadless Pacemaker Trial Success Launches Major Global Study - Stock Titan
New data supports Abbott Volt pulsed field ablation system - MassDevice
Abbott Laboratories Says New Clinical Study Data Showcase Long-Term, Sustained Benefits Of Abbott's Volt(TM) Pfa System For Patients With Afib - marketscreener.com
Abbott's Revolutionary AFib Treatment Achieves 83.5% Freedom from Arrhythmia in Landmark Study - Stock Titan
FDA says recall of Abbott HeartMate power unit is serious - MassDevice
FDA announces new recall of Abbott heart pump accessories over significant safety risks - Cardiovascular Business
Clinical Diagnostics Market: Trends, Growth, and Key Players - openPR.com
Medtronic seeks FDA nod for insulin pump (MDT:NYSE) - Seeking Alpha
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.69%
자본화:
|
볼륨(24시간):